In this episode, Rob Lustig — a researcher, an expert in fructose metabolism, and a former pediatric endocrinologist — discusses what’s wrong with the current food environment, and what we can do to reduce our chances of becoming part of the obesity, diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) epidemics. Rob recently earned a Master of Studies in Law because he believes that educating people about sugar from a scientific standpoint is only half the equation: the other half involves changing policy, which he explains in this episode.
We discuss:
What’s the difference between glucose and fructose? [7:00]; Do we have biomarkers that can give us some indication of average exposure to fructose over a given period of time? [14:20]; What’s the difference between ALT and AST? [18:45]; Inflammation, endothelial function, and uric acid [21:30]; Is there something that fructose does better than glucose? [23:45]; For children that undergo a remarkable shift from metabolic health to metabolic derangement, is there a concern that these kids suffer an epigenetic hit that makes it harder for them later in life? [26:15]; How many times do you have to introduce a savory food vs a sugary food to an infant before they will accept it? [29:30]; How are alcohol and fructose similar in how they affect the brain? [33:51]; Advice for parents and kids for creating a sustainable environment that's going to prevent them from running into metabolic problems [40:30]; Why do some populations have a higher risk for NAFLD? [45:42]; What causes NAFLD? [48:45]; Is insulin resistance the result of NAFLD or is NAFLD the result of insulin resistance? [56:00]; HRV, cortisol, and norepinephrine [1:00:30]; What are the actual mechanisms that links metabolic syndrome, insulin resistance, fatty liver, and type 2 diabetes? [1:03:00]; Is the food industry still saying that all calories contribute equally to adiposity and insulin resistance? [1:09:00]; What is the difference between soluble and insoluble fiber and why do you need both? [1:13:00]; How can we change the food system when 10 companies control almost 90 percent of the Calories we consume in the US? [1:15:00]; and More.Learn more at www.PeterAttiaMD.com
Connect with Peter on Facebook | Twitter | Instagram.
#323 - CRISPR and the future of gene editing: scientific advances, genetic therapies, disease treatment potential, and ethical considerations | Feng Zhang, Ph.D.
#322 - Bone health for life: building strong bones, preventing age-related loss, and reversing osteoporosis with evidence-based exercise | Belinda Beck, Ph.D.
#321 – Dopamine and addiction: navigating pleasure, pain, and the path to recovery | Anna Lembke, M.D.
#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape
#319 ‒ Peter's key takeaways on liver health, heart rate variability, AI in medicine, klotho, and lactate metabolism | Quarterly Podcast Summary #2
#318 ‒ Cycling phenom and Tour de France champion Tadej Pogačar reveals his training strategies, on-bike nutrition, and future aspirations
#317 ‒ Reforming medicine: uncovering blind spots, challenging the norm, and embracing innovation | Marty Makary, M.D., M.P.H.
#316 - AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations
Improve your decision-making, frameworks for learning, backcasting, and more | Annie Duke (#60 rebroadcast)
#315 ‒ Life after near-death: a new perspective on living, dying, and the afterlife | Sebastian Junger
#314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards | David Allison, Ph.D.
#313 - AMA #62: Protein’s impact on appetite and weight management, and uric acid's link to disease and how to manage levels
#312 - A masterclass in lactate: Its critical role as metabolic fuel, implications for diseases, and therapeutic potential from cancer to brain health and beyond | George A. Brooks, Ph.D.
#311 ‒ Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more
#310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.
#309 ‒ AI in medicine: its potential to revolutionize disease prediction, diagnosis, and outcomes, causes for concern in medicine and beyond, and more | Isaac Kohane, M.D., Ph.D.
Zone 2 training: impact on longevity and mitochondrial function, how to dose frequency and duration, and more | Iñigo San-Millán, Ph.D. (#201 rebroadcast)
#308 - AMA #61: Sun exposure, sunscreen, and skin health: relationship between sun exposure and skin cancer, vitamin D production, and photoaging, how to choose a sunscreen, and more
#307 ‒ Exercise for aging people: where to begin, and how to minimize risk while maximizing potential | Peter Attia, M.D.
#306 - AMA #60: preventing cognitive decline, nutrition myths, lowering blood glucose, apoB, and blood pressure, and more
Create your
podcast in
minutes
It is Free
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.